The Menarini Group

Industry

  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Urine-based Testing
    • Glucose Testing
    • Hematology, Coagulation

Other Names/Subsidiaries

  • A. Menarini Diagnostics S.r.l.
  • Berlin Chemie AG
  • Invida Group Private Limited
  • Lusofarmaco
  • Menarini Asia-Pacific Holdings (Menarini AP)
  • VaxYnethic
  • Stemline Therapeutics, Inc.
See more in Biomedtracker

Latest on The Menarini Group

Scrip

Arvinas/Pfizer’s Vepdegestrant Misses Best Case In Phase III

 
• By Jessica Merrill

Hopes that Arvinas/Pfizer’s estrogen receptor-targeting protein degrader vepdegestrant will show improved efficacy in breast cancer over selective estrogen receptor degraders (SERDs) appear dimmer fol

Scrip

Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regenxbio Calls On Nippon Shinyaku To

Scrip

Lilly’s Imlunestrant Shows Breast Cancer Benefit With Verzenio In All Comers

 
• By Jessica Merrill

Eli Lilly’s selective estrogen receptor degrader (SERD) imlunestrant has shown a benefit in a potentially large indication – as a treatment for patients with ER+/HER2- advanced breast cancer who have

Scrip

Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen

 
• By Joseph Haas

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Histogen’s Regenerative Medi